DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (the “Company”) today announced the limited commercial launch in the U.S. of ReActiv8, its implantable Restorative Neurostimulation™ system to ...
Anyone living with chronic low back pain frequently has one wish on their mind: “Fix. My. Lower. Back.” Now, a new clinically proven restorative treatment option called ReActiv8 could make a ...
DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced the publication of data from a single center, real-world study with one-year clinical follow-up of patients selected from the ...
Chronic lower back pain is something that can dramatically affect a person’s lifestyle and wellbeing. Whilst most back pain only lasts a short while and can be treated with medication or physiotherapy ...
Mainstay Medical International announced it has submitted a pre-investigation device exemption information package to the U.S. Food and Drug Administration for ReActive8, an implantable ...
ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction. Multifidus muscle dysfunction may be ...
DUBLIN, April 28, 2025--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield ("Anthem") has established favorable coverage for the company’s ReActiv8 ...
Founded in Minneapolis in 2008, Mainstay moved to Dublin in 2012. The latest funding will help it expand its ReActiv8 product in the US, Europe and Australia. Irish medtech company Mainstay Medical ...
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota
DUBLIN, February 04, 2026--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results